Travere Therapeutics, Inc.
TVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001438533
In the last 90 days, Travere Therapeutics, Inc. insiders filed 0 open-market purchases and 11 sales; 321 institutions reported holding it in 13F filings for Q2 2026, worth $5.98B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $4.86B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $80.1M in total
- 11
- 13F holdersQ2 2026, +60 vs. previous quarter
- 321
- 13F valueReported value at the end of Q2 2026
- $5.98B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $490.7M
- +110.5% year over year
- Net income, FY2025
- -$25.5M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $224.6M
- +36.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $25.5M (5.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 9.56M
- Shares sold short
- Change
- −1.35M
- −12.4% vs. previous
- Days to cover
- 4.74
- At average daily volume
Superinvestors holding TVTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TVTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Travere Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 (view filing)4:05 PM ET | Oct 15 | 4 days | Dube Eric MCHIEF EXECUTIVE OFFICER | SSale | −243.7K | $53.82 | −$13.1M | −36.0%432.9K after | 3 lots10b5-1 |
| Sep 17, 2026 (view filing)9:35 PM ET | Sep 15-16 | 2 days | Rote William E.Chief Research Officer | SSale | −209.0K | $62.83 | −$13.1M | −68.0%98.2K after | 6 lots10b5-1 |
| Sep 17, 2026 (view filing)9:35 PM ET | Sep 15-17 | 2 days | Heerma PeterEVP, CHIEF COMMERCIAL OFFICER | SSale | −283.2K | $63.06 | −$17.9M | −70.8%117.1K after | 7 lots10b5-1 |
| Sep 17, 2026 (view filing)9:33 PM ET | Sep 15 | 2 days | Inrig JulaEVP, Head of R&D & CMO | SSale | −44.7K | $62.34 | −$2.79M | −30.8%100.5K after | 4 lots10b5-1 |
| Sep 17, 2026 (view filing)9:32 PM ET | Sep 15 | 2 days | Reed Elizabeth EChief Legal Officer and GC | SSale | −37.5K | $62.34 | −$2.34M | −26.2%105.4K after | 4 lots10b5-1 |
| Sep 17, 2026 (view filing)9:31 PM ET | Sep 15-17 | 2 days | Dube Eric MCHIEF EXECUTIVE OFFICER | SSale | −400.0K | $63.48 | −$25.4M | −48.0%432.9K after | 8 lots10b5-1 |
| Sep 17, 2026 (view filing)9:30 PM ET | Sep 15 | 2 days | Cline Christopher R.CHIEF FINANCIAL OFFICER | SSale | −50.5K | $62.34 | −$3.15M | −36.6%87.5K after | 4 lots10b5-1 |
| Sep 17, 2026 (view filing)9:29 PM ET | Sep 15 | 2 days | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | SSale | −5.38K | $62.33 | −$335.0K | −11.3%42.4K after | 3 lots10b5-1 |
| Sep 11, 2026 (view filing)4:05 PM ET | Sep 10 | 1 day | Meckler Jeffrey ADirector | SSale | −20.0K | $67.31 | −$1.35M | −17.9%91.5K after | 4 lots10b5-1 |
| Sep 3, 2026 (view filing)4:05 PM ET | Sep 2 | 1 day | Cline Christopher R.CHIEF FINANCIAL OFFICER | SSale | −642 | $66.37 | −$42.6K | −0.5%118.0K after |
Top 10 13F holders, Q2 2026
See all 321 holdersThe largest institutional positions in Travere Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,324,191 | $643.3M | 0.26% | +11,324,191 | New |
| BlackRock, Inc. | 8,020,663 | $455.7M | 0.01% | +228,630+2.9% | Added |
| FMR LLC | 7,096,614 | $403.2M | 0.02% | −3,871,353−35.3% | Reduced |
| Bank of America Corp | 4,568,341 | $259.5M | 0.02% | +3,223,230+239.6% | Added |
| State Street Corp | 4,256,224 | $241.8M | 0.01% | −703,764−14.2% | Reduced |
| Vanguard Capital Management LLC | 4,108,694 | $233.4M | 0.00% | +62,882+1.6% | Added |
| Perceptive Advisors LLC | 3,752,574 | $213.2M | 3.31% | −389,977−9.4% | Reduced |
| Nomura Asset Management International Inc. | 2,812,514 | $159.8M | 0.24% | −457,999−14.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 2,569,356 | $146.0M | 0.20% | +1,592,356+163.0% | Added |
| Geode Capital Management, LLC | 2,371,887 | $134.8M | 0.01% | +2,328+0.1% | Added |
Holders of 5% or more of TVTX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Travere Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 11.90%10.6M shares | −0.90 ppfrom 12.80% | Feb 12, 20217 filings | Nov 14, 2025 | SEC |
| Armistice Capital, LLC | 13G/A | 9.96%8.88M shares | – | Aug 15, 20251 filing | Aug 15, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.50%6.69M shares | −1.90 ppfrom 9.40% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |
| FMR LLC | 13G/A | 6.10%5.71M shares | −1.60 ppfrom 7.70% | Jan 8, 20263 filings | Nov 5, 2026 | SEC |
| Bank of America Corp | 13G | 5.80%5.44M shares | New | Aug 12, 20261 filing | Aug 12, 2026 | SEC |